Maintenance to Lenalidomide Maintenance Treatment after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM)

PI: Ory Rouvio. Funded: BMS

Newly Diagnosed Multiple Myeloma After Transplant Drug: Teclistamab

PI: Ory Rouvio. Funded: EMN

Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Alnuctamab in Combination with Mezigdomide in Participants with Relapsed and/or Refractory Multiple Myeloma 2-4 (Phase 1b) or 1-3 (Phase 2a)

PI: Ory Rouvio

A phase 3 randomized trial comparing alnuctamab to belantamab mafodotin in patients with RRMM who received four lines of prior therapy

PI: Ory Rouvio. Funded: BMS

AN OPEN-LABEL, 2-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) + DARATUMUMAB+ LENALIDOMIDE VERSUS DARATUMUMAB + LENALIDOMIDE + DEXAMETHASONE IN TRANSPLANT-INELIGIBLE PARTICIPANTS WITH NEWLY- DIAGNOSED MULTIPLE MYELOMA

PI: Ory Rouvio. Funded: Pfizer

A Phase 1b Open-label Study to Evaluate the Safety and Tolerability of Intravenous Modakafusp Alfa as Part of Combination Therapy in Adult Patients With Multiple Myeloma

PI: Ory Rouvio